Article Text

Download PDFPDF

Implementing the routine immunisation data module and dashboard of DHIS2 in Nigeria, 2014–2019
  1. Faisal Shuaib1,
  2. Abdullahi Bulama Garba1,
  3. Emmanuel Meribole2,
  4. Samuel Obasi1,
  5. Adamu Sule3,
  6. Chimeremma Nnadi4,
  7. Ndadilnasiya Endie Waziri3,
  8. Omotayo Bolu4,
  9. Patrick M Nguku3,
  10. Margherita Ghiselli4,
  11. Oluwasegun Joel Adegoke4,
  12. Sara Jacenko4,
  13. Ester Mungure4,
  14. Saheed Gidado3,
  15. Idongesit Wilson3,
  16. Eric Wiesen4,
  17. Hashim Elmousaad4,
  18. Peter Bloland4,
  19. Louie Rosencrans4,
  20. Frank Mahoney4,
  21. Adam MacNeil4,
  22. Richard Franka4,
  23. John Vertefeuille4
  1. 1Department of Planning, Research and Statistics, National Primary Health Care Development Agency (NPHCDA), Abuja, Nigeria
  2. 2Department of Planning, Research and Statistics, Federal Ministry of Health (FMoH), Abuja, Nigeria
  3. 3National Stop Transmission of Polio (NSTOP), African Field Epidemiology Network (AFENET), Abuja, Nigeria
  4. 4Global Immunization Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
  1. Correspondence to Dr Margherita Ghiselli; mghiselli{at}


In 2010, Nigeria adopted the use of web-based software District Health Information System, V.2 (DHIS2) as the platform for the National Health Management Information System. The platform supports real-time data reporting and promotes government ownership and accountability. To strengthen its routine immunisation (RI) component, the US Centers for Disease Control and Prevention (CDC) through its implementing partner, the African Field Epidemiology Network-National Stop Transmission of Polio, in collaboration with the Government of Nigeria, developed the RI module and dashboard and piloted it in Kano state in 2014. The module was scaled up nationally over the next 4 years with funding from the Bill & Melinda Gates Foundation and CDC. One implementation officer was deployed per state for 2 years to support operations. Over 60 000 RI healthcare workers were trained on data collection, entry and interpretation and each local immunisation officer in the 774 local government areas (LGAs) received a laptop and stock of RI paper data tools. Templates for national-level and state-level RI bulletins and LGA quarterly performance tools were developed to promote real-time data use for feedback and decision making, and enhance the performance of RI services. By December 2017, the DHIS2 RI module had been rolled out in all 36 states and the Federal Capital Territory, and all states now report their RI data through the RI Module. All states identified at least one government DHIS2 focal person for oversight of the system’s reporting and management operations. Government officials routinely collect RI data and use them to improve RI vaccination coverage. This article describes the implementation process—including planning and implementation activities, achievements, lessons learnt, challenges and innovative solutions—and reports the achievements in improving timeliness and completeness rates.

  • vaccines

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

View Full Text

Statistics from


  • Handling editor Seye Abimbola

  • Contributors Conceptualisation, FS, ABG, EM, NEW, OB, PMN, PB, AM, JV, CN and SO; Methodology, JV, PB, CN, OB, NEW, SG, MG, OJA, EW, RF and LR; Software, AS, IW; Implementation, AS, IW, EW, LR, RF, MG, OB, OJA, SJ and EM; Formal Analysis, AS, IW, OJA and MG; Resources, AS, NEW, SG and OB.; Data Curation, AS, IW, OJA and MG; Writing—Original Draft Preparation, MG; Writing—Review and Editing, MG, OB, RF, HE, SJ, PMN and AS.

  • Funding The Nigeria DHIS2 Routine Immunisation Module and dashboard project received funding from the Bill & Melinda Gates Foundation (BMGF) and the US Centers for Disease Control and Prevention (CDC).

  • Disclaimer The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention / the Agency for Toxic Substances and Disease Registry. The authors did not receive specific funding for this paper.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement No additional data are available.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.